Access to this page has been denied
Source: seekingalpha.com
- Sanara Medtech trades at a steep 50% discount to its intrinsic value despite strong growth.
- Recent strategic pivots in sales and product focus have boosted revenue trajectory.
- Buy rating with $60 price target signals significant upside potential.
Sanara Medtech develops wound and skincare products, and this piece argues the stock is undervalued after early missteps were corrected. It breaks down improved financials, market positioning, and why investors should pay attention now. The analysis highlights a compelling entry point for a small-cap medtech play with real momentum.